Pcovery wins funding to improve fungal treatment options
As previously reported on this blog, the options available to clinicians treating fungal infections are narrow. As a whole, the pharmaceutical market is reluctant to invest heavily in developing new antifungal medication because of the comparatively small (though still extensive) market.
Clinicians and patients may find some happiness in the recent news that the Wellcome Trust has awarded £3.7
Clinicians and patients may find some happiness in the recent news that the Wellcome Trust has awarded £3.7
0 Response to "Pcovery wins funding to improve fungal treatment options"
Post a Comment